The company will institute the measures during the third quarter of 2022 with the financial effects expected to show up from the fourth quarter of the year onward, Babylon said in a news release.
Babylon said it has improved its adjusted EBITDA guidance from $295 million or less to $270 million or less for fiscal 2022, in which its revenue guidance of $1 billion or more will stay the same.
As Becker’s reported, the company has been busy expanding in the U.S. in recent years.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
